52 Week Range
As of on the National Stock Exchange of India ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Cipla Says U.S. FDA Inspection Ends With 4 Observations
Venus Remedies Announces Sale Of Elores To Cipla In India
Cipla Announces Launch Of Daptomycin For Injection
Cipla Limited is a holding company. The Company is a pharmaceutical company. The Company's strategic business units include Active Pharmaceutical Ingredients (APIs), Respiratory and Cipla Global Access. The Company's geographical segments include India, USA, South Africa and Rest of the World. The Company manufactures metered dose inhalers, dry powder inhalers, nasal sprays, nebulizers and a range of inhaled accessory devices. Cipla Global Access is a tender-based institutional business that concentrates on approximately four therapy areas: human immunodeficiency virus/acquired immuno deficiency syndrome (HIV/AIDS), malaria, multi drug-resistant tuberculosis and reproductive health. The Company offers its products for the therapeutic areas, including cardiovascular, children's health, dermatology and cosmetology, diabetes, HIV/AIDS, infectious diseases and critical care, malaria, neurosciences, oncology, ophthalmology, osteoporosis, respiratory, urology and women's health.
Biotechnology & Drugs
Yusuf K. Hamied
Non-Executive Chairman of the Board
Global Chief Executive Officer, Managing Director, Additional Director
Executive Vice Chairman of the Board
M. K. Hamied
Non-Executive Vice Chairman of the Board
Global Chief Financial Officer
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
Indian shares ended higher on Wednesday, with the broader NSE index breaching the 12,000 level for the first time since June 6 in intraday trade, helped by private banks and information technology companies.
** Shares of generic drugmaker Cipla Ltd rise as much as 3.41 pct to 538.75 rupees, their highest in a fortnight
Cipla Ltd, India's second-largest generic drugmaker by market capitalisation, reported on Wednesday a 17.1 percent drop in quarterly profit, dragged down by higher tax expenses and weak sales in domestic market.
Indian shares ended higher for a fifth straight session on Wednesday, with gains across most verticals, as investor sentiment was buoyed by a slew of upbeat quarterly results ahead of a key central bank policy meet which concludes on Thursday.
Cipla Ltd, India's second-biggest generic drugmaker by market capitalisation, reported a 17.1 percent fall in third-quarter profit on Wednesday, hurt by higher tax expenses.
** Shares of Cipla Ltd fall as much as 7.73 pct to 560.2 rupees, lowest since June 12
Cipla Ltd, India's second-largest drugmaker by market capitalisation, warned on Monday of "multiple headwinds" in the second half of the financial year after its quarterly profit fell short of analysts' estimates.
Drugmaker Cipla Ltd posted a nearly 11 percent fall in second-quarter profit on Monday, much lower than analyst expectations.
** India's third-largest drugmaker by market capitalisation Cipla Ltd's shares rise as much as 4.7 pct to 662.5 rupees, its highest since Nov 2017
Indian drugmaker Cipla Ltd posted quarterly profit well above analysts' expectations, helped by strong growth in the domestic market.
Cipla Ltd, India's third-largest drugmaker by market capitalisation, posted on Wednesday a more than 10 percent rise in its first-quarter profit, well above analysts' expectations.
- Note: Reuters has not verified this story and does not vouch for its accuracy
** April-June quarter should be weak for Cadila Healthcare Ltd and Lupin Ltd with sharp declines in U.S. sales q-o-q - Credit Suisse (CS)
** Cipla Ltd rises as much as 7.8 pct to 564.90 rupees - posts biggest intraday pct gain since Feb 8
Cipla Ltd, India's second-biggest drugmaker by market capitalization, posted a fourth-quarter profit on Tuesday, but missed street estimates.
Cipla Ltd, India's second-biggest drugmaker by market capitalization, posted a fourth-quarter profit on Tuesday, but missed analysts' estimates.
* MARCH QUARTER CONSOL NET PROFIT 1.79 BILLION RUPEES VERSUS LOSS OF 617.9 MILLION RUPEES LAST YEAR
* PARTNERS WITH MANNKIND FOR EXCLUSIVE MARKETING, DISTRIBUTION OF AFREZZA IN INDIA
* MANNKIND AND CIPLA ENTER AN EXCLUSIVE MARKETING AND DISTRIBUTION AGREEMENT FOR AFREZZA® IN INDIA
* GETS FINAL NOD FOR GENERIC VAZCULEP, GENERIC PHENYLEPHRINE HYDROCHLORIDE INJECTION USP, 10 MG/ML SINGLE-DOSE VIAL, GENERIC AROMASIN
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.